Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata

The study assessed the efficacy and safety of ritlecitinib, an oral medication for alopecia areata, over 24 months in 385 participants aged 12 and older. Results showed significant hair regrowth, with 61% of participants experiencing scalp hair regrowth after 2 years. Eyebrow and eyelash regrowth also improved, and 80% of participants were satisfied with their hair growth. The study highlighted the challenges in treating severe forms of alopecia areata, such as alopecia totalis/universalis, where discontinuation rates were higher due to lack of efficacy. Ritlecitinib demonstrated a favorable safety profile, with common adverse events including headache and nasopharyngitis. The study supports ritlecitinib as a promising long-term treatment option for alopecia areata.